Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 692 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sham Treatment Location Clear all

Conditions: Rosacea
Interventions: Anatabloc Cream, Placebo Cream; Other
Lead sponsor: Rock Creek Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Bradenton, Florida • New Orleans, Louisiana • New York, New York

Conditions: Arthroplasty
Interventions: 4975, highly purified capsaicin, Placebo; Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Birmingham, Alabama • Arcadia, California • Glendale, California + 7 more

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: San Diego, California • San Marcos, California • Miami, Florida

Conditions: IBS, Constipation
Interventions: Transcutaneous Electrical Acustimulation (TEA); Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease, Mild Cognitive Impairment
Interventions: Exelon Patch (rivastigmine transdermal system), Placebo Patches; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Submental Fat (SMF), Double Chin
Interventions: RJV001, Placebo; Drug
Lead sponsor: Rejuven Dermaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia
Interventions: 10% FBR containing bioadhesive gel, placebo gel; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Columbus, Ohio

Conditions: Knee Osteoarthritis
Interventions: Hylan G-F 20, Control; Device · Other
Lead sponsor: OhioHealth; Other
Eligibility: 40 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Nerve Injury
Interventions: Temporary Peripheral Nerve Stimulation System, Sham Temporary Peripheral Nerve Stimulation System; Device
Lead sponsor: Epineuron Technologies Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Gainesville, Florida • Orlando, Florida • New Orleans, Louisiana + 3 more

Conditions: Moderate to Severe Papulopustular Rosacea
Interventions: Ivermectin Cream, 1%, Placebo/Vehicle cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Osteoarthritis
Interventions: Diclofenac Sodium gel, 1%, Voltaren® Gel, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 35 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 44
States / cities: Mesa, Arizona • Anaheim, California • Canoga Park, California + 32 more

Conditions: Smoking Cessation
Interventions: rTMS Active 20Hz, rTMS Sham; Device
Lead sponsor: The City College of New York; Other
Eligibility: 21 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Alopecia, Radiodermatitis
Interventions: Norepinephrine; Drug
Lead sponsor: ProCertus BioPharm, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Psoriasis
Interventions: Placebo, SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: St Louis, Missouri • New York, New York • Portland, Oregon + 4 more

Conditions: Retinal Vein Occlusions
Interventions: Avastin, Osurdex; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus
Interventions: Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection; Drug · Device
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cerebrovascular Stroke
Interventions: Transcranial Magnetic Stimulation, Traditional Paired Associative Stimulation, Median Nerve Stimulation, Corticocortical Paired Associative Stimulation, Sham Paired Associative Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Post Operative Pain
Interventions: 0.25% bupivicaine will be injected at the study port site prior to incision, Saline will be injected at the study port site prior to incision, Saline will be in injected into the port site prior to closure, 0.25% bupivicaine will be injected into the port site prior to closure; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Opioid Use, Auriculotherapy, Pain, Abdominal, Cancer Pain, Liver Transplant
Interventions: NSS-2 BRIDGE, Sham NSS-2 BRIDGE; Device
Lead sponsor: Jacques E. Chelly; Other
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions: venlafaxine XR, placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 64 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more

Conditions: Alzheimer's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio

Conditions: Inflammation, Systemic Lupus Erythematosus
Interventions: NNC 0151-0000-0000, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Fibromyalgia
Interventions: MagPro TMS system (MagVenture, Denmark), Hypnosis; Device · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C

Mild Cognitive Impairment in Parkinson's Disease

RJV001 Study in Adults Receiving Abdominoplasty

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

Clinical Endpoint Study of Ivermectin 1% Cream

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke

Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy

Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

Rasagiline Rescue in Alzheimer's Disease Clinical Trial

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia